NCT03006419View on ClinicalTrials.gov

Basiliximab vs Low-dose Thymoglobulin Induction Therapy in Low Risk Kidney Transplant Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 1, 2016

Primary Completion Date

July 30, 2019

Study Completion Date

July 30, 2019

Conditions
Kidney Transplant RejectionKidney Transplant; Complications
Interventions
DRUG

Basiliximab

Standard induction therapy

DRUG

Thymoglobulin

Induction therapy

Trial Locations (1)

91897

Umae Hospital Especialidades 14 Adolfo Ruiz Cortines, Veracruz

All Listed Sponsors
lead

Coordinación de Investigación en Salud, Mexico

OTHER_GOV

NCT03006419 - Basiliximab vs Low-dose Thymoglobulin Induction Therapy in Low Risk Kidney Transplant Patients | Biotech Hunter | Biotech Hunter